Elusys and U.S. Army extend biodefense collaboration

19-Dec-2006

Elusys Therapeutics, Inc. announced that it has extended its Cooperative Research and Development Agreement (CRDA) with the United States Army Medical Research Institute of infectious diseases (USAMRIID). Under the agreement, both parties will continue to perform collaborative research to develop therapeutics against anthrax and other unspecified biowarfare agents, using Elusys' HP Antibody(TM) technology.

Elusys has received funding from the department of Defense and the National Institutes of Health to accelerate the development of Anthim and the HP Antibody technology. In total, the Company has received over $20 million from the U.S. Government for these programs.

According to the company, Anthim is a high-affinitymonoclonal antibody, targeting the anthrax toxin Protective Antigen, that has demonstrated significant efficacy against anthrax infection in lethal animal spore challenge studies. Further, Anthim has been demonstrated to be safe and well tolerated when administered with and without antibiotics in a human safety study. Anthim is being developed for prophylaxis and post-exposure treatment of inhalation anthrax.

Other news from the department science

More news from our other portals

All FT-IR spectrometer manufacturers at a glance